Steven P Fling

7PUBLICATIONS
77CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Molecular targetsNanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 12, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.

Aarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif

|Nov 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.

Randy F Sweis, Gurkamal S Chatta, Rohit K Jain

|Oct 02, 2024
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.

Kathryn Lurain, Ramya Ramaswami, Irene Ekwede

|Mar 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.

Kunle Odunsi, Feng Qian, Amit A Lugade

|Feb 05, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.

Nina Bhardwaj, Philip A Friedlander, Anna C Pavlick

|Jan 26, 2022
Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.

Thomas S Uldrick, Scott V Adams, Remi Fromentin

Pageof 2